Novel continuous blood purification pipeline

Abstract

The utility model discloses a novel continuous blood purification pipeline which comprises a purifier and a vein pot which are connected with each other, one end of the purifier is connected with the artery end of a human body, a 5% sodium citrate liquid bag and a pre-replacement liquid bag are connected between the artery end and the purifier, the purifier is connected with a dialysate bag, one end of the vein pot is connected with the vein end of the human body, and the other end of the vein pot is connected with the vein end of the human body. A rear replacement liquid bag is connected to the liquid pipe between the vein pot and the human vein end through a connecting assembly, a replacement liquid assembly of the machine and a replacement liquid extension assembly. According to the utility model, non-planned off-machine operation caused by vein kettle blood coagulation during local citric acid anticoagulation can be reduced, blood loss is reduced, and blood coagulation factor consumption caused by vein kettle blood coagulation and influence on the blood coagulation function are reduced; the use amount of citric acid can be reduced, blood coagulation in a vein pot is prevented, the occurrence rate of citric acid anticoagulation complications is reduced, the use of pumps is reduced, the risk of balance imbalance caused by inconsistent pump speeds is reduced, a finished product replacement liquid with higher calcium concentration can be used, and bone calcium loss is reduced.

Description

Technical Field

[0001] This utility model relates to the field of medical device technology, and in particular to a novel continuous blood purification pipeline. Background Technology

[0002] In the ICU, CRRT can no longer meet the patient's treatment needs simply by operating for 24 hours; it often needs to be maintained for 48 to 72 hours. In this case, citrate anticoagulation cannot only ensure that the filter does not clot, but must ensure that the entire extracorporeal circulation tubing does not clot, especially the venous chamber. Furthermore, during treatment, with the same therapeutic dose, post-replacement has a higher rate of harmful solute clearance than pre-replacement. To save on replacement fluid usage, reduce the patient's financial burden, and ensure treatment efficacy, post-replacement is often used in clinical practice.

[0003] Continuous blood purification (CBP) can continuously and gradually remove solutes from the patient's body, thereby producing an effective anti-inflammatory effect and reducing the level of inflammatory factors in the patient's body. However, due to the long overall duration of CBP treatment, coagulation often occurs during extracorporeal circulation, hindering treatment. Clinical statistics show that the incidence of coagulation during extracorporeal circulation is between 67.6% and 74.6%. By using low-dose local citrate anticoagulation technology, the adequacy of dialysis can be improved while ensuring anticoagulation effectiveness, and it offers better selectivity in CBP. Citrate can chelate ionic calcium in the patient's blood, thereby reducing ionic calcium levels and alleviating coagulation. The main implementation path of this technology involves pumping sodium citrate into the arterial end of the circulatory tubing. Subsequently, during extracorporeal circulation, citrate ions chelate with free calcium to form calcium citrate, slowing down the rate of prothrombin conversion to thrombin, thus achieving extracorporeal anticoagulation. In citrate technology, the most direct effect of citrate binding to extracorporeal blood is maintaining a low level of calcium ions after the filter, thus exerting an anticoagulant effect. Therefore, the adequacy of the anticoagulant effect of citrate depends crucially on the concentration of calcium ions after the filter. According to the research of James et al., the concentration of free calcium has a significant impact on the anticoagulant effect. The anticoagulant effect is optimal when the free calcium concentration is below 0.33 mmol / L; within the range of 0.33–0.56 mmol / L, the anticoagulant effect shows a concentration-dependent effect; and when the concentration is between 0.56–0.8 mmol / L, it still has a certain anticoagulant effect. However, when the free calcium concentration exceeds 0.8 mmol / L, its effect on coagulation function is no longer significant. However, Calatzis reached a different conclusion: the anticoagulant effect was optimal at a free calcium concentration of 0.25 mmol / L; within the range of 0.25–0.5 mmol / L, the anticoagulant effect also showed a concentration-dependent effect; and when the concentration exceeded 0.5 mmol / L, its effect on coagulation function became insignificant. Although these two studies differed in specific numerical values, they both reflected the important role of free calcium concentration in the anticoagulant process.

[0004] The calcium ion (iCa2+) in the calcium replacement solution is 1.6 mmol / L. During subsequent replacement, the replacement solution directly enters the venous chamber, causing an increase in the calcium ion concentration in the venous chamber, which leads to insufficient anticoagulation and clotting in the venous chamber. Utility Model Content

[0005] The purpose of this invention is to provide a novel continuous blood purification pipeline to solve the above-mentioned problems.

[0006] To solve the above-mentioned technical problems, the present invention adopts the following technical solution:

[0007] This utility model discloses a novel continuous blood purification tubing, comprising a purifier and a venous reservoir connected together. One end of the purifier is connected to the arterial end of the human body, and a 5% sodium citrate solution bag and a pre-replacement fluid bag are connected between the arterial end and the purifier. A dialysis fluid bag is connected to the purifier. One end of the venous reservoir is connected to the venous end of the human body, and a post-replacement fluid bag is connected to the fluid tubing between the venous reservoir and the venous end of the human body via a connecting component, a replacement fluid component built into the machine, and a replacement fluid extension component.

[0008] Furthermore, a waste liquid bag is connected to the purifier.

[0009] Furthermore, the connecting assembly includes a needle, an exhaust can, and a first female Luer connector connected in sequence via liquid tubing, the first female Luer connector being connected to the machine's built-in tubing.

[0010] Furthermore, a water-stop clamp is installed on the liquid pipe between the exhaust vessel and the first female Luer connector.

[0011] Furthermore, the replacement fluid extension assembly includes a second female Luer connector, an extension tube, and a male Luer connector connected in sequence. The second female Luer connector is connected to the end of the machine's built-in replacement fluid pipeline. An exhaust disc is installed on the second female Luer connector. The male Luer connector is connected to a tee connector at the venous end.

[0012] Compared with the prior art, the beneficial technical effects of this utility model are as follows:

[0013] This invention can reduce unplanned discontinuation of ventilators due to venous clotting, reduce tubing waste, reduce filter plug blockage, prevent non-return blood, reduce blood loss, and reduce the consumption of clotting factors caused by venous clotting, thereby affecting coagulation function. It can also reduce the amount of citrate used, prevent venous clotting, reduce the incidence of citrate anticoagulation complications, reduce pump use, reduce the risk of imbalance caused by inconsistent pump speeds, and allow the use of pre-made replacement fluid with higher calcium concentration to reduce bone calcium loss. Attached Figure Description

[0014] The present invention will be further described below with reference to the accompanying drawings.

[0015] Figure 1 This is a front view of the novel continuous blood purification pipeline of this utility model;

[0016] Figure 2 This is a schematic diagram of the connecting components;

[0017] Figure 3 Schematic diagram of the displacement fluid extension component;

[0018] Explanation of reference numerals in the attached diagram: 1. Purifier; 2. Infusion chamber; 3. 5% sodium citrate solution bag; 4. Pre-replacement fluid bag; 5. Dialysis fluid bag; 6. Post-replacement fluid bag; 7. Waste fluid bag; 8. Needle; 9. Exhaust chamber; 10. First female Luer connector; 11. Stop clamp; 12. Second female Luer connector; 13. Extension tube; 14. Male Luer connector; 15. Exhaust disc. Detailed Implementation

[0019] like Figure 1-3 As shown, a novel continuous blood purification pipeline includes a purifier 1 and a venous reservoir 2 connected together. One end of the purifier 1 is connected to the arterial end of the human body, and a 5% sodium citrate solution bag 3 and a pre-replacement fluid bag 4 are connected between the arterial end and the purifier 1. A waste fluid bag 7 is connected to the purifier 1.

[0020] The purifier 1 is connected to a dialysis fluid bag 5. One end of the venous reservoir 2 is connected to the human vein. The fluid tube between the venous reservoir 2 and the human vein is connected to a post-replacement fluid bag 6 through a connecting component, a replacement fluid component built into the machine, and a replacement fluid extension component.

[0021] The connecting assembly includes a needle 8, an air vent 9, and a first female Luer connector 10 connected in sequence via liquid tubing. The tubing length between the needle 8 and the air vent 9 is 2 cm, the air vent 9 has a capacity of 50 ml, the tubing length between the air vent 9 and the first female Luer connector 10 is 2-10 cm, the first female Luer connector 10 is connected to the machine's own tubing, and a water-stop clamp 11 is installed on the liquid tubing between the air vent 9 and the first female Luer connector 10.

[0022] The replacement fluid extension assembly includes a second female Luer connector 12, an extension tube 13, and a male Luer connector 14 connected in sequence. The second female Luer connector 12 is connected to the end of the replacement fluid pipeline provided with the machine. An exhaust disc 15 is installed on the second female Luer connector 12. The male Luer connector 14 is connected to a three-way connector at the venous end.

[0023] The embodiments described above are merely preferred embodiments of the present utility model and are not intended to limit the scope of the present utility model. Various modifications and improvements made to the technical solutions of the present utility model by those skilled in the art without departing from the spirit of the present utility model should fall within the protection scope defined by the claims of the present utility model.

Claims

1. A novel continuous blood purification tubing, characterized in that: The device includes a purifier (1) and a venous reservoir (2) connected together. One end of the purifier (1) is connected to the arterial end of the human body, and a 5% sodium citrate solution bag (3) and a pre-replacement fluid bag (4) are connected between the arterial end and the purifier (1). A dialysis fluid bag (5) is connected to the purifier (1). One end of the venous reservoir (2) is connected to the venous end of the human body, and a post-replacement fluid bag (6) is connected to the fluid tube between the venous reservoir (2) and the venous end of the human body through a connecting component, a replacement fluid component provided by the machine, and a replacement fluid extension component.

2. The novel continuous blood purification tubing according to claim 1, characterized in that: Waste liquid bag (7) is connected to the purifier (1).

3. The novel continuous blood purification tubing according to claim 1, characterized in that: The connecting assembly includes a needle (8), an exhaust can (9), and a first female Luer connector (10) connected in sequence via liquid tubing. The first female Luer connector (10) is connected to the tubing provided with the machine.

4. The novel continuous blood purification tubing according to claim 3, characterized in that: A water-stop clamp (11) is installed on the liquid pipe between the exhaust can (9) and the first female Luer connector (10).

5. The novel continuous blood purification tubing according to claim 3, characterized in that: The replacement fluid extension assembly includes a second female Luer connector (12), an extension tube (13), and a male Luer connector (14) connected in sequence. The second female Luer connector (12) is connected to the end of the replacement fluid pipeline provided with the machine. An exhaust disc (15) is installed on the second female Luer connector (12). The male Luer connector (14) is connected to the tee connector at the venous end.

Images